Anti-Human Placental Lactogen – HRP
Anti-Human Placental Lactogen – HRP
Product No.: H123
- -
- -
Clone 178 Target Placental Lactogen Formats AvailableView All Product Type Monoclonal Antibody Isotype IgG Applications ELISA Det |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen Purified Recombinant Human Placental Lactogen (>98%) Product Concentration 0.5 mg/ml Formulation This horseradish peroxidase conjugate is supplied in a specially formulated stabilization diluent.(Leinco Prod. No.: S509) Storage and Handling Stable for at least one year when stored at 2°C - 8°C. Do not freeze. Cross Reactivity Human prolactin <0.01%.
Human growth hormone <0.01%.
Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737510 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Mouse Anti-Human Placental Lactogen (Clone 178) recognizes Human Placental Lactogen. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. Background Human placental lactogen (HPL), also called human chorionic somatomammotropin, is a polypeptide placental hormone. Its structure and function is similar to that of human growth hormone. It modifies the metabolic state of the mother during pregnancy to facilitate the energy supply of the fetus.
HPL consists of 190 amino acids that are linked by two disulfite bonds and is secreted by the syncytiotrophoblast during pregnancy. Its molecular weight is 22,125. Like human growth hormone HPL is encoded by genes on chromosome 17q22-24. Its biologic half-life is 15 minutes.
HPL affects the metabolic system of the maternal organism. HPL increases production of insulin and IGF-1 and increases insulin resistance and carbohydrate intolerance. Chronic hypoglycemia leads to a rise in HPL. HPL induces lipolysis with the release of free fatty acids, increase in insulin secretion and insulin resistance. With fasting and release of HPL, free fatty acids become available for the maternal organism as fuel, so that relatively more glucose can be utilized by the fetus. Also, ketones formed from free fatty acids can cross the placenta and be used by the fetus. These events support energy supply to the fetus in states of starvation.
PubMed References & CitationsTechnical ProtocolsELISA Det Certificate of Analysis |
Related Products
Formats Available
- -
- -
Prod No. | Description |
---|---|
L103 | |
H123 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.